Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) saw a large decline in short interest during the month of March. As of March 13th, there was short interest totaling 40,790 shares, a decline of 25.7% from the February 26th total of 54,874 shares. Approximately 0.8% of the company’s shares are sold short. Based on an average trading volume of 51,489 shares, the short-interest ratio is presently 0.8 days.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Chemomab Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Chemomab Therapeutics has an average rating of “Hold” and a consensus price target of $25.00.

Chemomab Therapeutics Stock Down 5.8%

NASDAQ CMMB traded down $0.09 during trading on Friday, reaching $1.46. 41,042 shares of the stock traded hands, compared to its average volume of 66,213. Chemomab Therapeutics has a fifty-two week low of $1.35 and a fifty-two week high of $5.88. The firm has a market cap of $8.99 million, a price-to-earnings ratio of -0.57 and a beta of 0.41. The stock’s 50-day moving average price is $1.69 and its 200 day moving average price is $2.25.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its earnings results on Thursday, March 19th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Analysts anticipate that Chemomab Therapeutics will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Chemomab Therapeutics in the fourth quarter valued at about $31,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Chemomab Therapeutics during the fourth quarter worth about $85,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Chemomab Therapeutics during the 4th quarter valued at about $132,000. 46.05% of the stock is currently owned by institutional investors.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.